Cargando…

Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care

The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan is helpful for attaining simple and comprehensive understanding of medical care in Japan. Herein, we investigated the transition of anti-HIV-drug use in Japan over a 4-year period from fiscal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hiroyuki, Onoda, Toshihisa, Ishii, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564577/
https://www.ncbi.nlm.nih.gov/pubmed/36231441
http://dx.doi.org/10.3390/ijerph191912130
_version_ 1784808678902202368
author Tanaka, Hiroyuki
Onoda, Toshihisa
Ishii, Toshihiro
author_facet Tanaka, Hiroyuki
Onoda, Toshihisa
Ishii, Toshihiro
author_sort Tanaka, Hiroyuki
collection PubMed
description The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan is helpful for attaining simple and comprehensive understanding of medical care in Japan. Herein, we investigated the transition of anti-HIV-drug use in Japan over a 4-year period from fiscal year (FY) 2016 to FY 2019 using data on anti-HIV drugs that were extracted from the 3rd, 4th, 5th, and 6th NDB Open Data Japan. Then, the data were stratified by mechanism of action, single-tablet regimen (STR) or non-STR, age groups, and sex and analyzed. Throughout the study period, the prescription volume for tenofovir alafenamide fumarate as the backbone drug and integrase strand transfer inhibitors as the anchor drug increased. In FY 2019, STRs constituted approximately 44% of the total combination antiretroviral therapy regimens, 1.6 times higher than that in FY 2016 (27%). With the advent of newer drugs and regimens, the differences in anti-HIV drugs prescribed to patients of different ages and sex gradually diminished; however, differences were unremarkable in the first period, especially between sexes. The NDB Open Data Japan made it relatively easy to evaluate recent trends in anti-HIV prescription in Japan, indicating its usefulness for continuous surveys in this field.
format Online
Article
Text
id pubmed-9564577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95645772022-10-15 Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care Tanaka, Hiroyuki Onoda, Toshihisa Ishii, Toshihiro Int J Environ Res Public Health Article The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan is helpful for attaining simple and comprehensive understanding of medical care in Japan. Herein, we investigated the transition of anti-HIV-drug use in Japan over a 4-year period from fiscal year (FY) 2016 to FY 2019 using data on anti-HIV drugs that were extracted from the 3rd, 4th, 5th, and 6th NDB Open Data Japan. Then, the data were stratified by mechanism of action, single-tablet regimen (STR) or non-STR, age groups, and sex and analyzed. Throughout the study period, the prescription volume for tenofovir alafenamide fumarate as the backbone drug and integrase strand transfer inhibitors as the anchor drug increased. In FY 2019, STRs constituted approximately 44% of the total combination antiretroviral therapy regimens, 1.6 times higher than that in FY 2016 (27%). With the advent of newer drugs and regimens, the differences in anti-HIV drugs prescribed to patients of different ages and sex gradually diminished; however, differences were unremarkable in the first period, especially between sexes. The NDB Open Data Japan made it relatively easy to evaluate recent trends in anti-HIV prescription in Japan, indicating its usefulness for continuous surveys in this field. MDPI 2022-09-25 /pmc/articles/PMC9564577/ /pubmed/36231441 http://dx.doi.org/10.3390/ijerph191912130 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tanaka, Hiroyuki
Onoda, Toshihisa
Ishii, Toshihiro
Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title_full Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title_fullStr Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title_full_unstemmed Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title_short Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care
title_sort understanding the actual use of anti-hiv drugs in japan from 2016 to 2019: demonstrating epidemiological relevance of ndb open data japan for understanding japanese medical care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564577/
https://www.ncbi.nlm.nih.gov/pubmed/36231441
http://dx.doi.org/10.3390/ijerph191912130
work_keys_str_mv AT tanakahiroyuki understandingtheactualuseofantihivdrugsinjapanfrom2016to2019demonstratingepidemiologicalrelevanceofndbopendatajapanforunderstandingjapanesemedicalcare
AT onodatoshihisa understandingtheactualuseofantihivdrugsinjapanfrom2016to2019demonstratingepidemiologicalrelevanceofndbopendatajapanforunderstandingjapanesemedicalcare
AT ishiitoshihiro understandingtheactualuseofantihivdrugsinjapanfrom2016to2019demonstratingepidemiologicalrelevanceofndbopendatajapanforunderstandingjapanesemedicalcare